-
-
-
-
-
-
-
Leerink Starts Opus Genetics (IRD) at Outperform
-
-
-
-
-
-
-
Opus Genetics secures $155 million financing from Oberland Capital
-
-
-
-
-
-
-
LifeSci Capital Starts Opus Genetics (IRD) at Outperform
-
-
-
-
-
-
-
Opus Genetics advances LCA5 gene therapy toward pivotal trial after FDA meeting
-
-
-
-
-
-
-
Opus Genetics (IRD) Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint
-
-
-
-
-
-
-
Opus Genetics (IRD) Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases
-
-
-
-
-
-
-
Opus Genetics (IRD) Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330
-
418,855 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

